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Abstract 
 
Objectives: N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts mortality 
and the development of heart failure in hypertrophic cardiomyopathy (HCM). Mid-
regional pro-atrial natriuretic peptide (MR-proANP) is a stable byproduct of 
production of atrial natriuretic peptide. We sought to compare the prognostic value of 
MR-proANP and NT-proBNP in HCM.  
 
Methods: We prospectively enrolled a cohort of patients with HCM from different 
European centers and followed them. All patients had clinical, ECG and 
echocardiographic evaluation and measurement of MR-proANP and NT-proBNP at 
inclusion.  
 
Results: Of 357 patients enrolled, the median age was 52 (IQR: 36-65) years. MR-
proANP and NT-proBNP were both independently associated with age, weight, New 
York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF), wall 
thickness and left atrial dimension. 
During a median follow-up of 23 months, 32 patients had a primary end point defined 
as death (n=6), heart transplantation (n=8), left ventricular assist device implantation 
(n=1) or heart failure hospitalisation (n=17). Both NT-proBNP and MR-proANP 
(p<10
-4
) were strongly associated with the primary endpoint, and the areas under the 
ROC curves for both peptides were not significantly different. However, in a multiple 
stepwise regression analysis, the best model for predicting outcome was NYHA 1-2 
versus 3-4 (HR=0.35, CI 95% [0.16-0.77], p < 0.01), LVEF (HR = 0.96, CI 95% 
[0.94-0.98], p= 0.0005), and MR-proANP (HR=3.77, CI 95% [2.01-7.08], p<0.0001).  
 
Conclusions: MR-proANP emerges as a valuable biomarker for the prediction of 
death and heart failure related events in HCM patients. 
 
 
Key Words: natriuretic peptide, MR-proANP, NT-proBNP, hypertrophic 
cardiomyopathy 
 
Abbreviations: NYHA: New York Heart Association, HCM: hypertrophic 
cardiomyopathy, NT-proBNP: N terminal pro-brain natriuretic peptide, MR-proANP: 
mid-regional pro-atrial natriuretic peptide, LVEF: left ventricular ejection fraction, 
IQR: interquartile range, HR: hazard ratio, CI: confidence interval. 
 
Key questions:  
 
What is already known about this subject?  
Predicting prognosis in HCM remains challenging. High levels of BNP and NT-
proBNP are associated with cardiovascular events, heart failure and death in patients 
with HCM and these tests are recommended in the ESC guidelines on HCM. 
 
What does this study add? 
This study shows that another biomarker (ie MR-ProANP) might be at least as 
accurate as NT-proBNP for prognostication in patients with HCM. 
 
How might this impact on clinical practice? 
The use of MR-proANP might help to refine risk stratification and to assess the 
effects of novel interventions in patients with HCM. 
 
INTRODUCTION 
Hypertrophic cardiomyopathy (HCM) is a genetic myocardial disease defined by 
unexplained left ventricular hypertrophy, usually asymmetrical and involving the 
interventricular septum.
1 2
 It is generally associated with a normal or high left 
ventricular ejection fraction (LVEF) and impaired diastolic function. The clinical 
pattern is highly heterogeneous: many patients have no or mild symptoms during their 
whole life, but in some patients, HCM may lead to severe symptoms such as heart 
failure or sudden death. Heart failure is often associated with left atrial enlargement, 
which reflects increased left ventricular filling pressures secondary to left ventricular 
diastolic and, in some cases, systolic dysfunction.
3 4
 However predicting prognosis in 
HCM remains challenging.  
Natriuretic peptides are released from the heart due to increased myocardial wall 
stretch caused by volume and pressure overload.
5 6
 The diagnostic and prognostic 
values of BNP and NT-proBNP are now well-established in heart failure.
7 8
 In HCM, 
increased BNP and NT-proBNP concentrations have been associated with evidence of 
ventricular dysfunction, exercise intolerance, the development of heart failure and 
death.
9-12
 
MR-proANP is the mid-regional epitope of the ANP prohormone
13 
which, like NT-
proBNP, has a long circulating half-life. MR-proANP may be equal or superior to 
BNP or NT-proBNP for diagnosis and prognosis in HF.
14-16
 However, there are no 
published data on the clinical significance, particularly with regard to survival, of 
MR-proANP in patients with HCM. The aim of the present study was to determine 
the prognostic value of MR-proANP compared to NT-proBNP in patients with 
HCM.
17
 
  
  
 METHODS 
Patient selection 
The population consisted of patients with HCM recruited from the Eurogene Heart 
Failure Study, an observational multicentre cohort involving 11 European centres in 
France (Pitié-Salpêtrière Hospital, Paris and Ambroise Paré Hospital, Boulogne-
Billancourt), Germany (Marburg, Regensburg, Munster), Italy (Pavia), Portugal 
(Lisboa), Spain (Barcelona), Sweden (Umea)  and the United Kingdom (Hull), 
evaluating the genetics of patients with familial or sporadic dilated or hypertrophic 
cardiomyopathy. The study conforms to the principles outlined in the Declaration of 
Helsinki and was approved by all relevant ethics committees. Data were collected 
prospectively. The diagnosis of HCM was based on electrocardiogram and 
echocardiography: maximal left ventricular wall thickness >15 mm for index cases, 
>13mm or major abnormalities on electrocardiogram (Romhilt-Estes score >4 and/or 
pathological Q waves and/or significant ST-T changes) for relatives, without evidence 
of any other cause for left ventricular hypertrophy.
3
 Consecutive patients who 
fulfilled the criteria were screened to participate.  
 
Patient evaluation 
During an outpatient visit, informed consent was obtained. Patients then had a 
medical history taken, a cardiovascular examination, a 12-lead electrocardiogram and 
an echocardiography. Previous history of heart failure, previous procedures or 
surgery, New York Heart Association (NYHA) class, heart rate, sinus rhythm or atrial 
fibrillation, blood pressure and medical treatments were recorded. M-Mode and two-
dimensional transthoracic echocardiography studies were performed in the left lateral 
decubitus position and measurements made at enrolling sites according to a standard 
protocol. Left ventricular hypertrophy was assessed with echocardiography according 
to published criteria.
3
 Left ventricular end diastolic and end systolic diameters and left 
atrial diameters were obtained from M-Mode and two-dimensional images from the 
parasternal view. LVEF was calculated according to Simpson biplane method. Septal 
and posterior wall thicknesses were measured from the parasternal view. Left 
ventricular outflow tract gradient was measured at rest from continuous-wave 
Doppler and left ventricular outflow obstruction was defined as a maximal gradient > 
30 mmHg. Before starting, an echo sample was sent from each centre to an echo core 
lab. 
 Measurement of natriuretic peptides 
Venous blood samples were collected and transported as whole blood using a fast 
transport service (TNT company) from recruiting centres to Genethon (Evry, France). 
Samples were immediately centrifuged. Supernatant serum was stored at -80°C until 
the samples were analyzed in the Biochemistry Department of Pitie-Salpetriere 
Hospital, Paris. Serum NT-proBNP was measured by a two-site 
electrochemiluminescence immunoassay on a Roche Diagnostics E170 analyser. The 
limit of quantitation is <50 pg/ml, and the coefficients of variation of intra- and inter-
assay reproducibility are <5%. MR-proANP was measured by a sandwich 
chemiluminescence immunoassay on the KRYPTOR system (BRAHMS GmbH, 
Hennigsdorf, Germany). The limit of quantitation is 4.5 pmol/l, the coefficient of 
variation of intra-assay reproducibility was <5% and the coefficient of variation of 
inter-assay reproducibility was <6.5 %. 
(13)
 
 
Follow-up 
Patients were followed in their local centres for a median observation time of 23 
months. The investigator recorded the following endpoints during a clinic visit or by 
telephone: death, heart failure hospitalisation, cardiac transplantation or left 
ventricular assist device, and also intracardiac defibrillator implantation and 
appropriate shocks, septal myectomy and alcohol septal ablation.  
 
Statistical analysis 
Descriptive statistics used median (IQR) for quantitative variables and numbers 
(percentages) for binary variables. NT-proBNP and MR-proANP were log-
transformed (base 10) in order to normalize their probability density functions. 
Relationships with NT-proBNP and MR-proANP were assessed in univariate analyses 
using Spearman rank correlation coefficient tests for quantitative or ordinal variables 
(such as NYHA), and by Student’s t tests for binary variables. Variables with a p-
value lower than 0.10 in the univariate analyses were entered into stepwise multiple 
linear regressions, and only variables significant with a p-value lower than 0.05 were 
retained in the final models. 
The prognostic role of NT-proBNP and MR-proANP was assessed in the framework 
of survival analysis, with a compound criterion considered as the event. This endpoint 
was death, heart transplantation, left ventricular assist device or hospitalisation for 
heart failure. Missing data were not included in the analysis. The univariate step of 
the analysis used Kaplan-Meier estimation of the survival functions, and univariate 
Cox models for testing the relationships of each potential prognostic factor and the 
criterion. ROC curves were also performed to compare the areas under curve (AUC) 
of NT-proBNP and MR-proANP. The multivariate step involved the comparison of 
several Cox models. All computations were performed using the SAS V9.3 statistical 
package (SAS Institute, New-York). 
 
RESULTS 
Of 357 patients enrolled, the median age was 52 (IQR: 36-65), 57 % were male and 
88% were in NYHA functional class I or II (Table 1). Median maximal wall thickness 
was 20 (IQR 17-24) mm and left ventricular outflow tract obstruction was present in 
26 % of the patients at baseline. Median NT-proBNP was 550 (IQR: 202-1380) 
pg/mL and median MR-proANP was 107 (IQR: 58-184) pmol/L. Although all 
patients were clinically stable, 297 patients had an NT-proBNP concentration >125 
pg/mL, 246 a value >300 pg/mL and 172 had an MR-proANP concentration >120 
pmol/L, thresholds that have been proposed as useful for the diagnosis of heart failure 
in various clinical settings. 
 
Factors influencing natriuretic peptides levels in HCM 
MR-proANP and NT-proBNP were highly correlated (r= 0.76, p< 0.001) and both 
were directly correlated with age, NYHA class, posterior wall thickness and left atrial 
diameter and indirectly with weight. The correlation between left atrial diameter and 
MR-proANP was stronger than the correlation between left atrial diameter and NT-
proBNP (p<0.0001). Values of both markers were higher in women and in patients 
with atrial fibrillation or paced or if they had a previous hospitalisation for heart 
failure or a left ventricular outflow tract obstruction. MR-proANP correlated directly 
with serum creatinine and indirectly with LVEF. NT-proBNP correlated directly with 
septal and maximal wall thickness and indirectly with systolic blood pressure 
(Supplementary data, Tables 2a and 2b). Median MR-proANP was 64 pmol/L (IQR: 
39-141) in NYHA I patients, 137 pmol/L (IQR: 81-214) in NYHA II and 139 pmol/L 
(IQR: 95-211) in NYHA III and IV, while median NT-proBNP was 362 pg/mL (IQR: 
111-740) in NYHA I, 793 pg/mL (IQR: 307-1549) in NYHA II, 1041 pg/mL (IQR: 
362-2112) in NYHA III-IV (Figure 1).  
Multivariable linear regression models of log MR-proANP and log NT-proBNP 
revealed correlations with several variables (Table 2) for both peptides, including 
weight, age, NYHA class and left atrial diameter. In addition, a higher log MR-
proANP was associated with a lower LVEF. Higher log NT-proBNP was associated 
with lower systolic blood pressure and greater left ventricular wall thickness.  
 
Survival analysis 
Patients were followed for a median duration of 23 months (IQR 13-30 months) 
during which 32 primary endpoints were observed: 6 patients died, 1 patient had a left 
ventricular assist device, 8 patients underwent cardiac transplantation and 17 patients 
were hospitalized for heart failure. Patients who reached the primary endpoint had 
higher concentrations of MR-proANP and NT-proBNP than others (228 (IQR: 135-
341) pmol/L versus 101 (IQR:55-171) pmol/L and 2010 (IQR:785-2707) pg/mL 
versus 505 (IQR:196-1208) pg/mL respectively, both p< 10
-5
). Moreover, during 
follow-up, 12 patients had an alcohol septal ablation and 2 a septal myectomy. 
Intracardiac defibrillator were implanted in 12 patients and 5 patients had at least one 
appropriate shock, which were not predicted by the natriuretic peptides. 
Univariate analysis showed that log MR-proANP, log NT-proBNP, heart rate, 
NYHA, LVEF, posterior left ventricular wall thickness, left atrial diameter and 
systolic blood pressure were associated with the primary outcome (Table 3). The rate 
of events was 2.5 % in the lowest tertile (MR-proANP ≤ 70 pmol/mL), 5.8 % in the 
middle tertile (MR-proANP 70-155 pmol/mL), and 18.6 % in the highest tertile (MR-
proANP > 155 pmol/mL) (p=0.00002) (Figure 2). Figure 3 shows the comparison of 
areas under the ROC curve for the prediction of the primary end-point using NT-
proBNP (0.7417 [0.6425; 0.8409]) and MR-proANP (0.7703 [0.6820; 0.8586]), 
which were not significantly different (p=0.42). 
In multivariable analysis, log MR-proANP, LVEF and NYHA class III-IV were the 
only independent prognostic factors. Patients with either NYHA class III-IV or LVEF 
<50 % had a 27 % (18/66) rate of events compared to only 5 % (14/270) for those in 
NYHA class 1-2 and LVEF >50 %. In this lower-risk group, MR-proANP in the 2 
highest tertiles identified 13 of the 14 patients with events. On the opposite, in the 
higher-risk group (NYHA III -IV or LVEF < 50 %), the 2 lowest tertiles of MR-
proANP reclassified 31/48 patients without any events. 
 
 
  
DISCUSSION 
This analysis suggests that MR-proANP may be a useful marker of cardiac 
dysfunction and predictor of adverse outcomes in patients with HCM, but does not 
demonstrate definitively its superiority in these respects to NT-proBNP. MR-proANP 
and NT-proBNP are highly correlated, but some of their determinants are different. 
MR-proANP is mainly derived from the atria and therefore more closely related to 
left atrial structure and function. The left atrium may be the best barometer to 
integrate the effects of left ventricular, both diastolic and systolic, dysfunction. On the 
other hand, NT-proBNP may be predominantly derived from the ventricular 
myocardium and more closely related to left ventricular hypertrophy and dysfunction 
rather. The consequences of left ventricular dysfunction (ie: an increase in LA 
pressure) may be more important than more direct measures of left ventricular 
dysfunction.  
Many studies have reported increased plasma concentrations of BNP and NT-proBNP 
in patients with HCM
9-12 18-23 
and shown that they are associated with more left 
ventricular hypertrophy, more left ventricular outflow tract obstruction, left 
ventricular diastolic and systolic dysfunction, worse symptoms and reduced exercise 
tolerance. This is not unexpected, as the main source of BNP is cardiomyocytes and 
increased ventricular wall stress the major stimulus to its secretion.
24
 However, few 
studies have investigated the effects of HCM on plasma concentrations of atrial 
natriuretic peptide (ANP). Immunohistochemical analyses of endomyocardial 
biopsies from HCM patients confirm that ANP is expressed in ventricular 
myocardium in HCM
25 
and this expression is associated with myocardial disarray, 
hypertrophy of myocytes and fibrosis.  However, Briguori
18
 reported that plasma 
concentration of ANP in HCM was strongly associated with left atrial function, 
whereas BNP was strongly associated with obstruction. Only one study, including 
only 40 patients, has investigated MR-proANP in HCM patients, showing that 
amongst several biomarkers, MR-proANP was the only one associated with the extent 
of late gadolinium enhancement on MRI.
26 
As previous studies, we found a significant 
association between NYHA and natriuretic peptides although there was a significant 
overlap between NYHA 2 and 3-4 (Figure 1).  
Several single-centre studies have evaluated the prognostic value of natriuretic 
peptides in patients with HCM and confirmed that high concentrations of BNP or NT-
proBNP are associated with an increase in heart failure events and poorer survival.
11 12 
20-22 
We confirm this finding in a multicentre study for the first time. We also found 
that MR-proANP was a powerful prognostic marker to predict death, heart 
transplantation and heart failure events. Similar findings have been reported in heart 
failure.
15 16 27
 As discussed above, this may be because the left atrium is a better 
marker of overall left ventricular and mitral valve function and also reflects the effects 
of left atrial hypertension on pulmonary haemodynamics that may ultimately 
contribute to right heart dysfunction and systemic venous congestion. It is also 
possible that daily fluctuations in MR-proANP are smaller than for NT-proBNP 
making it a more stable marker.28 Finally, its predictive value seems particularly 
interesting in patients with a low-risk profile based on symptoms and 
echocardiography. 
Currently, there is no evidence that interventions to prevent disease progression are 
effective for patients with HCM and therefore there is no clinical mandate for early 
detection of worsening cardiac function unless it is to identify patients at risk of 
sudden arrhythmic death who required an implantable cardioverter defibrillator. 
However, MR-proANP could be a valuable research tool to identify patients at 
increased risk who should be considered for clinical trials of existing or novel 
treatments that might prevent or reverse progression. It is surprising how little 
evidence there is that beta-blockers, calcium antagonists or other agents improve 
outcome in HCM. Recently, clinical trials of a new class of agent, cardiac myosin 
inhibitors, have begun. MR-proANP might be helpful to identify risk and might also 
be a measure of a successful intervention.  
 
Study limitations.  
Our study is a post-hoc analysis of the multicentre Eurogene Heart Failure cohort. 
However, enrolment and data-collection were standardized and follow-up was 
prospective. Some echocardiographic measurements such as left atrial volume, 
pulmonary pressure, or parameters of diastolic function, were not available for all the 
patients and therefore were not included in the model for prognostic analysis. 
Likewise, left ventricular outflow tract obstruction was evaluated only at rest and not 
during Valsalva or exercise. Patients were enrolled predominantly in tertiary centers 
with a special interest in HCM for the purposes of genetic evaluation. Thus, most 
patients did not have advanced disease and had no or few symptoms. This may 
account for the relatively low event rate. On the opposite, the proportion of patients 
needing left ventricular assist device or heart transplantation might appear relatively 
high. However, our rate of death or heart failure-related events is very comparable to 
other large cohorts of HCM patients from tertiary centers (around 2.2 %/ year).
11 12
 
The generalisability of our results to less selected population should be addressed in 
further studies.   
 
In summary, this multicentre study of patients with HCM suggests that MR-proANP, 
if not superior to NT-proBNP, is strongly related to cardiac dysfunction and 
prognosis. MR-proANP might be a useful tool for monitoring patients with HCM to 
identify patients at increased risk who would be potential candidate to existing or 
novel interventions.  
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Figure 1:  Box and whisker plot showing the relationship between New York 
Association functional class and NT-proBNP and MR-proANP. Data show median, 
interquartile range (boxes) and full-range. 
 
 
 
 
Figure 2: Kaplan–Meier analysis showing cumulative rates of survival in 357 patients 
with hypertrophic cardiomyopathy, stratified into tertiles according to MR proANP 
values. 1
st
 tertile (MR-proANP < 70 pmol/mL), 2
nd
 tertile (MR-proANP 70-155 
pmol/mL), 3
rd
 tertile (MR-proANP > 155 pmol/mL). 
 
 
Figure 3: Areas under the receiver-operating curve (AUC) for NT-proBNP (solid 
line) and MR-proANP (dashed line) for the prediction of death, heart transplantation, 
left ventricular assist device implantation and heart failure hospitalisations.  
Table 1. Baseline characteristics 
 
  Age 52 (36-65) 
  Male 204 (57) 
History  
  Syncope 77 (21) 
  Hospitalisation for Heart failure 49 (13) 
Clinical presentation  
  Systolic blood pressure, mm Hg 125 (110-140) 
  Diastolic blood pressure, mmHg 75 (70-80) 
  Heart rate, beats/min 65 (58-74)  
  Weight, kg 73 (64-82) 
  NYHA (%)  
                  NYHA 1 137 (41)  
                  NYHA 2 160 (47)  
                  NYHA 3-4 41 (12)  
  Atrial fibrillation (%) 10 
Biology  
  Serum creatinine (mg/dl) 1.00 (0.89-1.20) 
  MR-proANP (pmol/L) 107 (58-184) 
  NT-proBNP (ng/L) 550 (202-1380) 
Echocardiography data  
  LV end diastolic dimension, mm 46 (41-49) 
  LV ejection fraction, % 65 (59-71)  
           LV ejection fraction < 50 %  41 (11) 
  Posterior wall thickness, mm 11 (10-14) 
  Septal wall thickness, mm 18 (15-21) 
  Maximum wall thickness, mm 20 (17-24)  
  Left atrial diameter, mm 44 (39-50) 
Therapy  
  Medications  
        Beta-receptor antagonist 174 (49) 
        Calcium channel blocker 78 (22) 
        Renin angiotensin system inhibitors 53 (15) 
        Antiarrhythmic drug 50 (14) 
        Disopyramide 2  
  Devices  
        Pace-maker at baseline 46 (13)  
        Intracardiac defibrillator at baseline                          20 (6) 
        Intracardiac defibrillator at study end 32 (9)  
Procedures  
        Septal myectomy at baseline 25 (7) 
        Septal myectomy at study end 27 (8) 
        Alcohol septal ablation at baseline 5 (1) 
        Alcohol septal ablation at study end 17 (5) 
  
Values are median (IQR) or n (%). (NYHA, n=337; Systolic blood pressure, n=350; LV ejection 
fraction, n= 354; left atrial diameter, n=350; serum creatinine, n=211)  
  
 Table 2.  Multivariable analysis of the independent determinants of MR-proANP and 
NT-proBNP 
  
 log MR-proANP log NT-proBNP 
Variable Parameter 
estimate 
Standard 
Error 
p Parameter 
estimate 
Standar
d error 
p 
Intercept 4.60   6.30   
NYHA 
    1 
    2 
    3-4 
 
-0.43 
-0.10 
0. 
 
0.12 
0.11 
<0.0001  
-0.81 
-0.33 
0. 
 
0.21 
0.20 
 
<0.0001 
Age (y) 0.009 0.002 <0.001 0.011 0.004 0.0125 
Weight (kg) -0.017 0.003 <0.0001 -0.029 0.005 <0.0001 
SBP (mmHg) - - - -0.011 0.004 0.0046 
Max LVWT (mm) - - - 0.085 0.012 <0.0001 
LAD (mm) 0.035 0.004 <0.0001 0.038 0.008 <0.0001 
LVEF (%) -0.006 0.003 0.0235 - - - 
SBP: systolic blood pressure; max LVWT: maximal left ventricular wall thickness; LAD: left 
atrial diameter; LVEF: left ventricular ejection fraction 
ventricular wall thickness; LAD: left atrial diameter; LVEF: left ventricular ejection fraction 
 
  
Table 3. Univariate and multivariable analysis for prediction of the primary composite 
endpoint 
                      
 
All-cause mortality, transplantation, LVAD, hospitalisation for heart failure 
 Univariate Multivariable 
 
HR (95% CI) p-value HR (95% CI) p-value 
Log MR-proANP  4.25 (2.45-7.38) <0.0001 3.77 (2.01-7.08) <0.0001 
Log NT-proBNP 2.33 (1.66-3.27) <0.0001   
Age (years) 1.0 (0.99-1.03) 0.3   
Weight (kg) 0.99 (0.97-1.02) 0.66   
SBP 0.98 (0.96-0.99) 0.02   
Heart rate 1.03 (1.01-1.06) 0.01   
NYHA (1-2 / 3-4) 3.4 (2.1-5.5) <0.0001 0.35 (0.16-0.77) 0.0086 
LVEF (%) 0.95 (0.93-0.97) <0.0001 0.96 (0.94-0.98) 0.0005 
LVEDD (mm) 1.04 (0.99-1.07) 0.055   
PWT (mm) 1.13 (1.01-1.27) 0.033   
SWT (mm) 0.98 (0.92-1.04) 0.55   
Maximal WT (mm) 0.99 (0.93-1.06) 0.91   
LAD (mm) 1.08 (1.04-1.12) <0.0001   
SBP: systolic blood pressure, LVEF: left ventricular ejection fraction; LVEDD: left 
ventricular end diastolic diameter, PWT: posterior wall thickness, SWT: septal wall 
thickness; LAD: left atrial diameter; LVAD: left ventricular assist device. HR= Hazard ratio; 
CI=confidence interval 
 
